CIAPIN1抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Raji cells, Primary antibody: P08158(CIAPIN1 Antibody) at dilution 1/597, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08158(CIAPIN1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08158(CIAPIN1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

CIAPIN1 (Cytokine-Induced Apoptosis Inhibitor 1), also known as **Anamorsin**, is a highly conserved protein involved in diverse cellular processes, including apoptosis regulation, signal transduction, and cell cycle control. Initially identified as a downstream effector of cytokine signaling pathways, CIAPIN1 plays a critical role in inhibiting apoptosis induced by cytokine withdrawal, particularly in hematopoietic cells. It interacts with key molecular partners such as the MEK/ERK pathway components and Bcl-2 family proteins, underscoring its importance in maintaining cell survival and homeostasis. Structurally, CIAPIN1 contains conserved domains that facilitate its participation in redox-sensitive processes and iron-sulfur cluster biogenesis, linking it to mitochondrial function and oxidative stress responses.

CIAPIN1 antibodies are essential tools for studying its expression, localization, and functional mechanisms. These antibodies enable researchers to detect CIAPIN1 in various experimental setups, including Western blotting, immunofluorescence, and immunohistochemistry. Dysregulation of CIAPIN1 has been implicated in multiple pathologies, such as cancers (e.g., leukemia, gastric, and liver cancers), cardiovascular diseases, and autoimmune disorders. Overexpression of CIAPIN1 is often associated with tumor progression, chemoresistance, and poor prognosis, while its downregulation correlates with increased apoptosis and disease severity in non-cancer contexts.

The development of CIAPIN1-specific antibodies has advanced both basic research and clinical exploration. These reagents aid in elucidating CIAPIN1’s role in disease mechanisms and its potential as a therapeutic target or biomarker. Ongoing studies continue to unravel its complex interactions and tissue-specific functions, highlighting CIAPIN1 as a multifaceted player in cellular health and disease.